CN112870328A

CN112870328A - Application of pinellia ternate heart-fire purging decoction in preparation of medicine for treating ulcerative colitis

Info

Publication number: CN112870328A
Application number: CN202110401041.1A
Authority: CN
Inventors: 浦益琼; 张彤; 王微微; 许聪聪; 王梓冰
Original assignee: Shanghai University of Traditional Chinese Medicine
Current assignee: Shanghai University of Traditional Chinese Medicine
Priority date: 2021-04-14
Filing date: 2021-04-14
Publication date: 2021-06-01

Abstract

The invention relates to application of pinellia ternate heart-fire purging decoction in preparation of a medicine for treating Ulcerative Colitis (UC). The invention discusses the treatment effect and relevant mechanism of the pinellia ternate heart-fire clearing decoction extracted by the ancient method and the modern method on UC rats, and the results show that the extracts of the ancient method and the modern method can reduce the severity of UC, including reducing DAI score and intestinal weight index, improving colon injury, increasing the IL-4 and IL-10 levels of serum and reducing IL-1 beta and TNF-alpha of serum; at similar doses, the ancient extracts were more effective than the modern extracts. The invention proves that the ancient Chinese medicinal compound pinellia ternate heart-fire purging decoction is an effective candidate medicament for treating UC, is beneficial to promoting the application of the pinellia ternate heart-fire purging decoction in the clinical treatment of the UC, and also provides a new medicament for treating the UC.

Description

Application of pinellia ternate heart-fire purging decoction in preparation of medicine for treating ulcerative colitis

Technical Field

The invention relates to the field of traditional Chinese medicines, in particular to application of pinellia ternate heart-fire purging decoction in preparation of a medicine for treating ulcerative colitis.

Background

Ulcerative Colitis (UC), also known as chronic nonspecific Ulcerative colitis, is an inflammatory bowel disease with unknown etiology and mainly invading the rectal and colonic mucosa and submucosa, and clinically, symptoms of the digestive tract such as diarrhea, abdominal pain, mucopurulent bloody stool are typical manifestations, and various complications can appear in long-term inflammation, wherein the colorectal carcinogenesis consequence is the most serious and is considered as one of precancerous lesions of colon cancer [1 ]. Currently, the treatment of UC mainly includes drug treatment and surgical treatment [2], clinically, aminosalicylic acid preparations and glucocorticoid medicines are mostly adopted for treatment, such as mesalazine [3] and budesonide [4], many novel medicines are sequentially developed and applied to treat UC [5], but most of the diseases are difficult to cure. Because the mechanism of the disease is not clear, no specific medicine for radically curing UC exists at present, and the disease is listed as one of the world intractable diseases by WHO.

Western medicines have quick response and short administration period, but have more side effects and cannot cure the diseases [6,7 ]. In recent years, more and more traditional Chinese medicines are proved to have various beneficial effects such as anti-inflammation, antioxidation and anti-tumor, and the effects are proved to have important effects on the aspect of resisting intestinal diseases by a plurality of researches, and the research results show that the traditional Chinese medicines have the characteristics of high safety and few side effects. There is a great deal of research related to the treatment of ulcerative colitis with traditional Chinese medicines.

The pinellia ternate heart-fire purging decoction is a classic and famous traditional Chinese medicine prescription, is published in Shang Han Lun (treatise on Cold-induced diseases), and consists of seven medicines of pinellia ternate, scutellaria baicalensis, coptis chinensis, rhizoma zingiberis, ginseng, honey-fried licorice roots and Chinese dates, and the prescription mainly comprises 'pungent taste and bitter taste, both reinforcing and purging and cold and heat combined application'. Studies show that the pinellia ternate heart-fire clearing decoction has anti-inflammatory and anti-oxidation effects [8 ]. The study takes the formula as a study object, observes the curative effect of the pinellia ternate heart-fire clearing decoction on UC rats, and further discusses the action mechanism of the pinellia ternate heart-fire clearing decoction.

Disclosure of Invention

The invention aims to provide a new medical application of pinellia ternate heart-fire purging decoction aiming at the defects in the prior art.

In order to solve the technical problems, the technical scheme adopted by the invention is as follows:

application of pinellia ternate decoction for purging heart fire in preparation of medicine for treating ulcerative colitis is provided.

As a preferred embodiment of the present invention, the pinellia ternate decoction for purging heart fire is prepared according to an ancient extraction method.

As a preferred example, the ancient extraction method comprises the following specific steps: taking 50-70 parts of pinellia ternate, 40-50 parts of scutellaria baicalensis, 40-50 parts of rhizoma zingiberis, 40-50 parts of ginseng, 40-50 parts of honey-fried licorice root and 10-20 parts of coptis chinensis according to the weight part ratio, taking 10-14 jujubes, adding 1500-2500 parts of water, decocting until the water content is 0.5-0.7 time of the original water content, removing dregs of the decoction, decocting until the water content is 0.25-0.35 time of the original water content, concentrating and drying.

More preferably, the ancient extraction method comprises the following specific steps: taking 60 parts of pinellia ternate, 45 parts of scutellaria baicalensis, 45 parts of rhizoma zingiberis, 45 parts of ginseng, 45 parts of honey-fried licorice root and 15 parts of coptis chinensis according to the weight part ratio, taking 2000 parts of water to decoct to 0.6 time of the original water addition amount, removing medicine residues, decocting to 0.3 time of the original water addition amount, concentrating and drying.

As another preferred embodiment of the present invention, the medicament is for:

a) decreasing the DAI score;

b) reducing the intestinal weight index;

c) improving the degree of colon injury and inflammation;

d) increasing serum IL-4, IL-10 levels; and/or

e) Reduce serum IL-1 beta and TNF-alpha levels.

The invention has the advantages that:

the invention discusses the treatment effect and relevant mechanism of the pinellia ternate heart-fire clearing decoction on rats with Ulcerative Colitis (UC). Specifically, 54 SD rats were randomly divided into 9 groups: normal group, model group, positive control group, ancient extraction method low dose group (BXD-AED-L), medium dose group (BXD-AED-M), high dose group (BXD-AED-H), modern extraction method low dose group (BXD-MED-L), medium dose group (BXD-MED-M), high dose group (BXD-MED-H), each group comprises 6, except normal group, each group adopts a method of injecting 70mg/kg ethanol solution containing TNBS (2, 4, 6-trinitrobenzene sulfonic acid) into rectum to establish ulcerative colitis model. The next day after molding, the normal group and the model group had free diet and drinking water, and the other groups had the corresponding dose of the drug for 7 consecutive days. The weight change, the fecal characteristics and the hematochezia condition of rats in each group are checked and recorded every day in the whole experimental period, DAI scoring is carried out according to a scoring standard, the intestinal weight index, the colon tissue appearance damage and the histopathological damage of the rats are detected 7 days after administration, and the concentration of interleukin IL-4, IL-10, IL-1 beta, IL-6 and tumor necrosis factor TNF-alpha in serum is detected by an ELISA method. The results show that in vivo experiments, DAI, rat intestinal weight index, colon tissue appearance damage, histopathological damage and concentration levels of IL-4, IL-1 beta and TNF-alpha in serum show that the BXD-AED group and the BXD-MED group can reduce the severity of UC, and the BXD-AED group has better effect than the BXD-MED group under similar dosage. The invention shows that the ancient formula pinellia ternate heart-fire clearing decoction is an effective candidate medicament for treating UC, is beneficial to promoting the use of the pinellia ternate heart-fire clearing decoction in the clinical UC treatment, and also provides a new medicament for the UC treatment.

Drawings

Figure 1. effect of BXD on UC rat DAI, colon body mass index, colon macroscopic inflammation score, and serum cytokines. (A) An index of disease activity; (B) an intestinal weight index; (C) a colon macroscopic inflammation score; (D) serum IL-4 concentration; (E) serum IL-10 concentration; (F) serum IL-1 β concentration; (G) serum TNF- α concentration; (H) serum IL-6 concentration. a. A normal group; b. a model group; a SASP group; bxd-AED-L group; bxd-AED-M group; bxd-AED-H group; BXD-MED-L group; BXD-MED-M group; bxd-MED-H group.

FIG. 2. Effect of ban Xia Xie Xiexing Tang on TNBS-induced pathological changes of appearance and colon tissue of UC rat colon. (A) The appearance of the colon; (B) pathological changes in colon tissue (x 100). a. A normal group; b. a model group; a SASP group; bxd-AED-L group; bxd-AED-M group; bxd-AED-H group; BXD-MED-L group; BXD-MED-M group; bxd-MED-H group.

Detailed Description

The following detailed description of the present invention will be made with reference to the accompanying drawings.

Example 1

1. Materials and methods

1.1 Experimental animals

54 clean SD male rats with weight of 175-.

1.2 Experimental drugs

The modern extraction method of the pinellia ternate decoction for purging fire comprises the following steps: all decoction pieces were purchased from Shanghai hong Qiao Chinese herbal pieces Limited, pinellia ternate 15g (batch No. 181024), dried ginger 9g (batch No. 190102), baikal skullcap root 9g (batch No. 190215), prepared licorice root 9g (batch No. 181221), ginseng 9g (batch No. 190403), coptis chinensis 3g (batch No. 190114), and Chinese date 4 (batch No. 181229), all of which were identified by Zhang Hongmei doctor of Shanghai Chinese medicine university academy of medicine.

Preparation of pinellia ternate heart-fire clearing decoction extract: taking 7 medicines in the prescription, adding 12 times of water for reflux extraction for 1 hour for the first time, adding 10 times of water for reflux extraction for 0.5 hour for the second time, combining the two extracting solutions, filtering, concentrating and drying the filtrate under reduced pressure at 60 ℃, crushing and sieving by a No. 3 sieve to obtain the traditional Chinese medicine.

The pinellia ternate heart-fire purging decoction is prepared by an ancient extraction method: 60g of pinellia ternate, 45g of scutellaria baicalensis, 45g of rhizoma zingiberis, 45g of ginseng, 45g of honey-fried licorice root, 15g of coptis chinensis and 12 Chinese dates, wherein the sources and the batches of all decoction pieces are the same.

Preparation of pinellia ternate heart-fire clearing decoction extract: the preparation method comprises the steps of taking the medicines in the formula, adding 2000mL of water, decocting to 1200mL, removing medicine residues, concentrating to 600mL, concentrating and drying at 60 ℃ under reduced pressure, crushing, and sieving with a No. 3 sieve.

1.3 Primary reagents

Salicylazosulfapyridine (SASP, Dalian American biotechnology, Inc., A0322A), TNBS and sodium pentobarbital (Sigma-Aldrich, Inc.), liquid paraffin (national group chemical, Inc., lot 20190830), ethanol (national group chemical, Inc., analytical grade, lot 20190729), benzidine (Shanghai Yuen Biotech, Inc., R004986), hydrogen peroxide (national group chemical, Inc., analytical grade, lot 20190423), 4% paraformaldehyde-general-purpose tissue fixative (69061800, biosharp, Inc.), and ELISA kit (Shanghai Guantai biotechnology, Inc.).

1.4 Experimental methods

1.4.1 molding method:

the room temperature was 23 + -1 deg.C and humidity was 20% under a 12 hour light/dark cycle. Animals were allowed ad libitum access to water throughout the study. Prior to the experiment, all rats were allowed to acclimate for one week.

TNBS modeling [9 ]: except for the normal group, rats in each group were fasted for 24 hours before molding, and were anesthetized by intraperitoneal injection of 2% sodium pentobarbital (0.15mL/100g) at a dose of 30mg/kg, and then molded by the following procedures: a syringe connected with a polyethylene tube is used for pumping 5 percent TNBS solution (0.14mL/100g) and 50 percent ethanol according to the dose of 70mg/kg and mixing the TNBS solution and the ethanol according to the proportion of 1: 1 uniformly, the head end of the polyethylene tube is coated with a little paraffin oil and inserted into the colon of a rat at a position which is about 8cm away from the anus, and the mixed solution is slowly injected. After the injection, the anus of the rat is clamped by the dovetail clip, the rat is hung for 15 minutes with the head facing downwards, and after the rat is laid down for 15 minutes, the dovetail clip is taken down until the rat is awake naturally and then can eat freely.

1.4.2 grouping and administration:

54 SD rats were randomly divided into 9 groups (n ═ 6/group): normal group, model group, positive control group (SASP sulfasalazine enteric coated tablet, 500mg/kg), ancient extraction low dose group (BXD-AED-L), middle dose group (BXD-AED-M), high dose group (BXD-AED-H), modern extraction low dose group (BXD-MED-L), middle dose group (BXD-MED-M), high dose group (BXD-MED-H), see Table 1. The next day after molding, the normal group and the model group had free diet and drinking water; the other treatment groups were dosed with the corresponding dose of the drug for 7 consecutive days. During the study, rats were examined daily for body weight, fecal characteristics and rectal bleeding.

TABLE 1 grouping and administration

1.5 detection index

1.5.1 Disease Activity Index (DAI)

Throughout the experimental period, the rats of each group were examined and recorded daily for weight change, fecal characteristics, and fecal blood, and scored according to scoring criteria, which are shown in Table 2[10 ]. The scores for each index were added daily as Disease Activity Index (DAI) with a score of up to 10.

TABLE 2 Disease Activity Index (DAI) score criteria

Note: DAI ═ (weight loss score + stool trait + occult blood score)/3; detecting fecal occult blood using a benzidine method; the body weight of the model on the day is taken as the basic body weight.

Benzidine method: a small amount of excrement is picked by a bamboo stick, so that the glass slide is convenient, 2 drops of benzidine ice acetic acid solution are dripped on the excrement, and 2 drops of 3% hydrogen peroxide are dripped. The color reaction was observed within 2min, and the blue coloration was positive. The intensity of positive is judged according to the shade of the color, and the color is not developed to be negative after 2 min.

1.5.2 intestinal weight index

After the last administration, the rats in each group were fasted for 24h, anesthetized, hemolyzed in the abdominal aorta, the entire colon segment was removed, cut along the longitudinal axis of the intestine, rinsed with normal saline, the length of the colon measured with a vernier caliper, and precisely weighed. The ratio of the weight to the length is used as an intestinal weight index (g/cm) for judging the degree of colonic edema or shortening caused by inflammation, and is an important index for evaluating the severity of colitis.

1.5.3 Colon appearance tissue injury score

The colon tissue was washed clean with saline and evaluated for apparent inflammation, with the scoring criteria shown in Table 3[2 ].

TABLE 3 Colon appearance tissue damage score criteria

1.5.4 histopathological injury score

Approximately 0.5cm of colon tissue was cut, fixed with 4% formalin, paraffin-embedded and sectioned, deparaffinized, and stained with hematoxylin-eosin (HE). The changes of ulcer and inflammatory cell infiltration are observed under a microscope, and the pathological histology scoring is carried out according to related standards, and the scoring standards are shown in a table 4[11 ].

TABLE 4 histopathological Scoring criteria

1.5.5 ELISA method for detecting IL-4, IL-10, IL-1 beta, TNF-alpha and IL-6 level in serum

Taking blood from abdominal aorta, standing for 2h, centrifuging (5000r/min, 10min), taking upper layer serum, standing at-80 deg.C for storage, and determining IL-4, IL-10, IL-1 beta, TNF-alpha and IL-6 content in serum according to ELISA kit.

2. Statistical treatment

The experimental data are expressed by Mean ± SD, data processing and analysis are performed by SPSS 25.0(IBM, New York, NY, USA) software, pairwise comparison of the multiple sets of sample means is performed by One-Way ANOVA analysis of variance, pairwise comparison of the group means is performed by least significant difference method (LSD), and P <0.05 is taken as significant difference.

3. Results

3.1 DAI and intestinal weight index

Compared with the normal group, the DAI score and the intestinal weight index of the model group are obviously increased after TNBS modeling (P <0.01 or P <0.05), and the result indicates that TNBS induced modeling is successful. Compared with the model group, the DAI score of rats in each treatment group is obviously reduced (P < 0.01); compared with the model group, the intestinal weight indexes of the BXD-AED-L/M group and the BXD-MED-L group (P <0.01) are obviously reduced, which shows that the congestion and edema of the colon of the rat are relieved, and the positive control group, the ancient extraction method high dose group and the modern extraction method high and medium dose group have no obvious change (P >0.05) compared with the model group. BXD, especially ancient extracts, has good protective effect on UC at low and medium dosage. The results are shown in FIGS. 1A and 1B.

3.2 macroscopic assessment of colonic Damage

The texture of the colonic fold of the normal group of rats is clear, the mucous membrane is smooth, and no ulcer, erosion, congestion or edema is seen. In contrast, in most rats in the model group, the colons are seriously adhered to the surrounding tissues and are difficult to peel off, segmental peripheral ulcers are visible about 8cm away from the anus, the intestinal walls are obviously thickened, and the surfaces of the ulcers have tan pseudomembrane-like necrotic attachments. As shown in FIG. 1C, the macroscopic colon inflammation score of each treated group was significantly lower (P <0.01 or P <0.05) compared with that of the model group, and inflammatory symptoms such as ulcer, congestion, edema and the like of the BXD-AED group and the BXD-MED group were significantly relieved to different degrees compared with that of the model group, suggesting that the BXD obtained by the two extraction methods has significant recovery effect on the colonic injury of the UC rat. Appearance of colon tissue, the results are shown in FIG. 2A.

3.3 Effect of pinellia Tuber decoction for purging Heart fire on histopathology

Normal rats had intact colonic mucosa, well-arranged glands and no inflammatory cell infiltration or ulceration. The colon mucosa and glands in the model group are mostly damaged and shed, the arrangement of the glands is disordered, and inflammatory cells infiltrate. The BXD-AED-L/M group showed different degrees of gland defects, and the arrangement was not uniform, and there was a small amount of inflammatory cell infiltration, slightly improved compared with the model group. The BXD-MED-L/M/H group can show slight gland shedding and inflammatory cell infiltration, and the glands are arranged neatly; the colon mucous membrane of BXD-AED-H group and SASP group is basically recovered completely, the arrangement of glands is relatively regular, no obvious inflammatory cell infiltration exists, and the improvement is obvious compared with the model group. The results are shown in FIG. 2B.

3.4 Effect of pinellia Ternate XieXiexin decoction treatment on serum IL-4, IL-10, IL-1 beta, TNF-alpha and IL-6 levels

In order to further explore the anti-inflammatory action mechanism of the pinellia ternate heart-fire clearing decoction on the ulcerative colitis of the rats, the concentration levels of cytokines IL-4, IL-10, IL-1 beta, TNF-alpha and IL-6 related to colitis in the serum of each group of rats are measured by an ELISA method, and the results show that: under the action of TNBS, the level of anti-inflammatory factor IL-4 in the serum of the model group is obviously reduced, and compared with the model group, the concentration of IL-4 in the serum of each treatment group is obviously increased (P is less than 0.05, and P is less than 0.01), which shows that the pinellia ternate heart-fire clearing decoction has a promoting effect on the increase of IL-4 expression; the concentration of the anti-inflammatory factor IL-10 in the SASP group and the BXD-AED-M/H group is obviously improved compared with that in the model group (P <0.05 and P <0.01), and the IL-10 level of other treatment groups is improved but has no obvious difference with that in the model group; under the induction of TNBS, the level of proinflammatory factor IL-1 beta in a model group is obviously increased, and compared with the model group, the level of IL-1 beta in serum of SASP group, BXD-AED group and BXD-MED-L/H group is obviously reduced (P is less than 0.01) after drug treatment, which shows that the pinellia ternate heart-fire clearing decoction has an inhibiting effect on IL-1 beta; compared with the model group, the levels of proinflammatory factors TNF-alpha in the SASP group, the BXD-AED group and the BXD-MED-M/H group are all obviously reduced, and the difference has statistical significance (P <0.05, P < 0.01); the IL-6 concentration in the serum of each treatment group of the model group and the pinellia ternate heart-fire purging decoction has no significant difference. The results are shown in FIGS. 1D-H.

4. Discussion of the related Art

BXD has also been used to treat various gastrointestinal disorders including chronic atrophic gastritis [12], peptic ulcer [13], diarrhea [14] and colon cancer [15], with significant efficacy. Recent studies [16,17] have demonstrated that BXD contains a variety of natural components such as baicalin, baicalein, berberine, etc. that are biologically active against UC. Thus, this study explored the in vivo effects of BXD on the UC model.

However, the ancient literature on BXD preparation methods and modern clinical applications and industrial production different. Therefore, it is important to discuss the possible differences between extracts under different extraction methods.

In the preparation method recorded in Shanghai treatise, seven medicines in the formula are decocted with 2000mL of water to obtain 1200mL of liquid medicine, and the liquid medicine is continuously concentrated to 600mL after the dregs of a decoction are removed. This approach is slightly different from the conventional practice of reflux commonly used in the pharmaceutical field today. The special decocting method recorded in the traditional Chinese medicine works, including the method of removing dregs and then decocting, is also applied to other ancient Chinese medicine compound, such as Xiaochaihu decoction, licorice heart-fire clearing decoction and the like. Whether the pharmacological effects of the extracts extracted under different conditions are different is also a key problem in the modern development and application of the traditional Chinese medicine classic compound. In addition, there are significant differences between ancient and modern weight measurement methods. For example, 1 or two in the Han Dynasty corresponds to about 15g (modern weight unit), while it is also explained as 3g [18] in the current study of Chinese medicine prescriptions, and 1 or two in the current Chinese daily life corresponds to 50 g. On the basis of exploring the influence of preparation method and measurement problem in the traditional Chinese medicine classical method research process, BXD-AED and BXD-MED are taken as research objects in the research, and the UC resistance effect of the BXD-AED and the BXD-MED is compared.

UC is a non-specific bowel disease with clinical symptoms including diarrhea, abdominal pain, mucopurulent bloody stool and weight loss [8]Common UC models include oxazolinone, sodium dextran sulfate (DSS) -induced mice and TNBS-induced rat acute or chronic models [19]. In the TNBS colitis model, ethanol is essential and can be used to provide access to intestinal epithelial cells, which in turn impairs barrier function and allows TNBS to penetrate the intestinal wall, further leading to haptenation of colonic proteins or microbiota-derived proteins and TNP-specific CD4⁺T cell and antibody production.

In the in vivo pharmacological experiments of this study, a UC rat model was established using 5% TNBS-ethanol, with SASP as a positive control. The BXD-AED group and the BXD-MED group were divided into 3 dose groups of low, medium and high, respectively. The results show that each group of BXD can effectively reduce the DAI score of UC rats (P <0.05), and the results show that both AED and MED can improve the weight loss, diarrhea and hematochezia conditions of the UC rats. The intestinal weight index and macroscopic inflammation score also prove that the BXD-AED group has certain advantages compared with the BXD-MED group, in particular the colonic edema degree of the BXD-AED-L group (equivalent to 12.6g/kg of crude drug quantity) is lighter. In the BXD-MED-H group, the indexes are obviously different when the dosage is close to the dosage (equivalent to 11.36g/kg of crude drug). These trends indicate that the manufacturing process may be more important than the problem of dosage metering.

UC, a form of inflammatory bowel disease, is closely associated with inflammation [20 ]. During the process of inflammation, a series of cytokines are released to participate in the inflammatory reaction. Therefore, this study also used ELISA to detect levels of inflammatory-related cytokines in serum to explore the potential anti-inflammatory mechanisms of BXD. In summary, the BXD treated group had elevated levels of anti-inflammatory factors (IL-4, IL-10) and reduced levels of pro-inflammatory factors (IL-1. beta., TNF-. alpha.). The results of these serum cytokine measurements showed that the cytokine levels in the BXD-AED-L group (D in FIGS. 1D-H) were superior to those in the BXD-MED-H group (i in FIGS. 1D-H), which further demonstrates the importance of the dessertion method. In addition, the difference between the anti-UC effects of the BXD-AED group and the BXD-MED group indirectly suggests that the difference may be related to the difference of the active ingredient content in the decoction.

IL-4 is an anti-inflammatory cytokine that inhibits the differentiation of Th17 cells. The results of Huang et al show that inhibition of Th17 differentiation contributes to the treatment of DSS-induced colitis in mice, while upregulation of IL-4 also prevents UC [21 ]. In this study, the model group IL-4 levels were significantly lower than the normal group and the IL-4 levels were significantly higher in each treatment group than the model group (P <0.05 or 0.01) after TNBS induction. This result indicates that BXD has significant anti-inflammatory effects.

IL-1 β is an inflammatory factor and represents a high level of inflammation. Castro-Dopico et al recently demonstrated that IL-1. beta. is upregulated during active UC [22 ]. In active disease, IL-1 β is localized in immune cell infiltration of the lamina propria, in contrast to the almost exclusive expression of epithelial cell layers under non-inflammatory conditions [23 ]. During UC, activated macrophages produce excessive amounts of cytokines, including IL-1 β. In the study, the IL-1 beta level in UC rat serum after TNBS modeling is obviously increased compared with the normal group. After BXD administration, most treatment groups significantly suppressed this trend.

Ghorbaninejad et al also demonstrated that TNF- α is closely related to UC and plays an important role in the induction of inflammatory responses to UC [24 ]. Furthermore, they found that increased activity of TNF family members may lead to apoptosis of intestinal epithelial cells. Increased epithelial apoptosis can damage the intestinal mucosa, eventually leading to inflammation. Studies by Che et al have shown that natural chemicals can significantly inhibit TNF- α secretion and reduce UC-related inflammation and apoptosis [25 ]. At the same time, Wang et al have recently investigated the efficacy of treatment of UC, and their studies have demonstrated that TNF- α is effectively inhibited [20 ]. In this study, the model group showed significantly higher levels of TNF- α expression than the normal group, whereas most of the BXD treated groups showed significantly lower levels of TNF- α expression. The levels of TNF- α were even lower in the BXD-AED-M/H and BXD-MED-M/H groups than in the normal group. This result strongly indicates the inhibitory effect of BXD on TNF- α expression in UC rat serum.

5. Conclusion

This study evaluated the effect of BXD prepared by different extraction methods on TNBS-induced rats. The results indicate that both AED and MED methods can reduce the severity of UC as shown by the DAI score, the gut weight index, visual and histological assessment of colon damage, and the results for serum IL-4, IL-10, IL-1 β, TNF- α, and IL-6. At similar doses, the BXD-AED group was more effective than the BXD-MED group. The combination of the research results shows that the ancient Chinese herbal compound BXD is an effective candidate drug for treating UC in modern times.

Reference to the literature

1.Yashiro,M.,Ulcerative colitis-associated colorectal cancer.World J Gastroenterol,2014.20(44):p.16389-97.

2.Bing,X.,et al.,EGCG Maintains Th1/Th2 Balance and Mitigates Ulcerative Colitis Induced by Dextran Sulfate Sodium through TLR4/MyD88/NF-kappaB Signaling Pathway in Rats.Can J Gastroenterol Hepatol,2017.2017:p.3057268.

3.Yorulmaz,E.,et al.,Therapeutic effectiveness of rectally administered fish oil and mesalazine in trinitrobenzenesulfonic acid-induced colitis.Biomed Pharmacother,2019.118:p.109247.

4.Abdalla,M.I.and H.Herfarth,Budesonide for the treatment of ulcerative colitis.Expert Opin Pharmacother,2016.17(11):p.1549-59.

5.Alasmary,F.A.S.,et al.,Novel quinazoline and acetamide derivatives as safe anti-ulcerogenic agent and anti-ulcerative colitis activity.Saudi Pharm J,2018.26(1):p.138-143.

6.Gilca,G.E.,et al.,Sarcoidosis associated with infliximab therapy in ulcerative colitis:A case report.Medicine(Baltimore),2017.96(10):p.e6156.

7.Huang,P.H.,et al.,Mesalazine-related lung disease in a patient with ulcerative colitis:A case report.Medicine(Baltimore),2018.97(48):p.e13242.

8.Chen,G.,et al.,Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice.J Ethnopharmacol,2015.166:p.149-56.

9.Morris,G.P.,et al.,Hapten-induced model of chronic inflammation and ulceration in the rat colon.Gastroenterology,1989.96(3):p.795-803.

10.Yan,Y.,et al.,Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis.Iran J Basic Med Sci,2019.22(12):p.1452-1461.

11.Gálvez,J.,et al.,Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat.Alimentary Pharmacology&Therapeutics,2001.15(12):p.2027-2039.

12.Ji,Q.,et al.,Banxia Xiexin Decoction in the treatment of chronic atrophic gastritis:A protocol for systematic review and meta-analysis.Medicine(Baltimore),2020.99(42):p.e22110.

13.Chen,S.,et al.,Effect of Banxia Xiexin decoction on Helicobacter pylori-related peptic ulcers and its possible mechanism via the TGF-beta/Smad signaling pathway.J Tradit Chin Med,2018.38(3):p.419-426.

14.Lu,H.,et al.,Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.Integr Cancer Ther,2018.17(4):p.1109-1114.

15.Li,K.,et al.,Effect of a modified Banxia Xiexin decoction plus chemotherapy on stage colon cancer.J Tradit Chin Med,2019.39(2):p.251-257.

16.Cui,H.,et al.,Berberine Regulates Treg/Th17 Balance to Treat Ulcerative Colitis Through Modulating the Gut Microbiota in the Colon.Front Pharmacol,2018.9:p.571.

17.Liang,S.,et al.,The Comparative Study of the Therapeutic Effects and Mechanism of Baicalin,Baicalein,and Their Combination on Ulcerative Colitis Rat.Front Pharmacol,2019.10:p.1466.

18.Du,M.B.,Discussion on drug dosage in Treatise on Febrile Diseases.China Journal of Chinese Materia Medica,2019.44(22):p.5012-5016.

19.Wirtz,S.,et al.,Chemically induced mouse models of acute and chronic intestinal inflammation.Nat Protoc,2017.12(7):p.1295-1309.

20.Wang,G.,et al.,Protective Effect of Methane-Rich Saline on Acetic Acid-Induced Ulcerative Colitis via Blocking the TLR4/NF-kappaB/MAPK Pathway and Promoting IL-10/JAK1/STAT3-Mediated Anti-inflammatory Response.Oxid Med Cell Longev,2019.2019:p.7850324.

21.Huang,X.L.,et al.,Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation.World J Gastroenterol,2016.22(22):p.5201-10.

22.Castro-Dopico,T.,et al.,Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis.Immunity,2019.50(4):p.1099-1114 e10.

23.Ranson,N.,et al.,NLRP3-Dependent and-Independent Processing of Interleukin(IL)-1 beta in Active Ulcerative Colitis.International Journal of Molecular Sciences,2019.20(1).

24.Ghorbaninejad,M.,et al.,Contribution of NOTCH signaling pathway along with TNF-alpha in the intestinal inflammation of ulcerative colitis.Gastroenterol Hepatol Bed Bench,2019.12(Suppl1):p.S80-S86.

25.Che,L.,et al.,Anti-inflammatory and anti-apoptosis activity of taraxasterol in ulcerative colitis in vitro and in vivo.Exp Ther Med,2019.18(3):p.1745-1751.

The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.

Claims

1. Application of pinellia ternate decoction for purging heart fire in preparation of medicine for treating ulcerative colitis is provided.

2. The use as claimed in claim 1, wherein the ban Xia Xiexin Tang is prepared by ancient extraction method.

3. The use of claim 2, wherein the ancient extraction method comprises the following specific steps: taking 50-70 parts of pinellia ternate, 40-50 parts of scutellaria baicalensis, 40-50 parts of rhizoma zingiberis, 40-50 parts of ginseng, 40-50 parts of honey-fried licorice root and 10-20 parts of coptis chinensis according to the weight part ratio, taking 10-14 jujubes, adding 1500-2500 parts of water, decocting until the water content is 0.5-0.7 time of the original water content, removing dregs of the decoction, decocting until the water content is 0.25-0.35 time of the original water content, concentrating and drying.

4. The use of claim 3, wherein the ancient extraction method comprises the following specific steps: taking 60 parts of pinellia ternate, 45 parts of scutellaria baicalensis, 45 parts of rhizoma zingiberis, 45 parts of ginseng, 45 parts of honey-fried licorice root and 15 parts of coptis chinensis according to the weight part ratio, taking 2000 parts of water to decoct to 0.6 time of the original water addition amount, removing medicine residues, decocting to 0.3 time of the original water addition amount, concentrating and drying.

5. The use according to claim 1, wherein the medicament is for:

a) decreasing the DAI score;

b) reducing the intestinal weight index;

c) improving the degree of colon injury and inflammation;

d) increasing serum IL-4, IL-10 levels; and/or

e) Reduce serum IL-1 beta and TNF-alpha levels.